Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2023-189557

Published: 2023

Journal Articles

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2023-182256

Published: 2023

Journal Articles

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Gautam Borthakur, Zeev Estrov, Tapan M. Kadia, Farhad Ravandi, Naveen Pemmaraju, Graciela Nogueras-Gonzalez, Heather Schneider, Rosmy John, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero, Xiao Qin DONG

Blood (2023) 142 (Supplement 1): 1873.

https://doi.org/10.1182/blood-2023-178110

Published: 2023

Journal Articles

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Blood (2022) 140 (Supplement 1): 9773–9775.

https://doi.org/10.1182/blood-2022-169213

Published: 2022

Journal Articles

Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome : A Single-Center Retrospective Study

Kunhwa Kim, Kelly S. Chien, Faustine Ong, Tapan M. Kadia, Elias J. Jabbour, Yesid Alvarado, Koji Sasaki, Carlos E. Bueso-Ramos, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Xiao Qin Dong, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 1527.

https://doi.org/10.1182/blood-2021-154457

Published: 2021

Journal Articles

Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias J. Jabbour, Zeev E. Estrov, Tapan M. Kadia, Farhad Ravandi, Kelly S. Chien, Graciela M. Nogueras González, Xiao Qin Dong, Stefan Faderl, Heather Schneider, Rosmy B. John, Meghan Anne Meyer, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 3674.

https://doi.org/10.1182/blood-2021-151493

Published: 2021

Journal Articles

Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents

Guillermo Montalban Bravo, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Zeev E. Estrov, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Kelly S. Chien, MD, Graciela M. Nogueras González, MPH, Xiao Qin Dong, Stefan Faderl, MD, Heather Schneider, BSN, RN, Rosmy B. John, MSN, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139942

Published: 2020

Journal Articles

Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam Borthakur, MD, Kiran Naqvi, MD MPH, Naval Daver, MD, Guillermo Montalban Bravo, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MD MSCE, Elias Jabbour, MD, Yesid Alvarado, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly A. Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-140521

Published: 2020

Journal Articles

Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-141100

Published: 2020

Journal Articles

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Michael Andreeff, MD PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4240.

https://doi.org/10.1182/blood-2019-129598

Published: 2019

Journal Articles

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Tapan Kadia, MD, Farhad Ravandi, MD, Naval Daver, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Elias Jabbour, Steven M. Kornblau, MD, Srdan Verstovsek, MD, William Wierda, MD PhD, Jan A Burger, MD PhD, Zeev Estrov, MD, Courtney DiNardo, MD, Xiao Qin Dong, Naveen Pemmaraju, MD, Maro Ohanian, DO, Koichi Takahashi, MD, Stephany Hendrickson, RN, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 4779.

https://doi.org/10.1182/blood.V126.23.4779.4779

Published: 2015

Journal Articles

Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.

Elias J. Jabbour, MD, Naval G. Daver, MD, Tina (Xiao Qin) Dong, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, M.D., Hady Ghanem, MD, Stefan Faderl, MD, Gautam Borthakur, M.D., Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 2824.

https://doi.org/10.1182/blood.V120.21.2824.2824

Published: 2012

Journal Articles

Clinical Characterization, Prognostic Implications, and Response to Therapy In Patients with Myelodysplastic Syndrome (MDS) and Chromsome 17 Abnormality: A Single Institutional Experience

Tapan Kadia, MD, Gautam Borthakur, MD, Stefan Faderl, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Susan O'Brien, MD, Elias Jabbour, MD, Xiao Qin Dong, Sherry A. Pierce, RN, BS, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2010) 116 (21): 2930.

https://doi.org/10.1182/blood.V116.21.2930.2930

Published: 2010

NARROW

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome : A Single-Center Retrospective Study

Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents

Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome

Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.

Clinical Characterization, Prognostic Implications, and Response to Therapy In Patients with Myelodysplastic Syndrome (MDS) and Chromsome 17 Abnormality: A Single Institutional Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only